Evidence Feed - LARVOL VERI

PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 2 days (New B) nivolumab Sensitive : B Bristol-Myers Squibb Press Release - 2d	nivolumab Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - 2 days nivolumab Sensitive : B Bristol-Myers Squibb Press Release - 2 days - (New B)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) ivosidenib Sensitive : A1 ASCO 2023 - 3d	ivosidenib Sensitive: A1 - Approval ASCO 2023 - 3 days ivosidenib Sensitive : A1 ASCO 2023 - 3 days - (New B)
PTEN overexpression	Squamous Cell Carcinoma of Head and Neck	PTEN overexpression	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials ASCO 2023 - 3 days (New C3) afatinib Sensitive : B ASCO 2023 - 3d	afatinib Sensitive: B - Late Trials ASCO 2023 - 3 days afatinib Sensitive : B ASCO 2023 - 3 days - (New C3)
HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) talazoparib Sensitive : B ASCO 2023 - 3d	talazoparib Sensitive: B - Late Trials ASCO 2023 - 3 days talazoparib Sensitive : B ASCO 2023 - 3 days - (New B)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AZD3759 Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) AZD3759 Sensitive : B ASCO 2023 - 3d	AZD3759 Sensitive: B - Late Trials ASCO 2023 - 3 days AZD3759 Sensitive : B ASCO 2023 - 3 days - (New B)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval Future Medicine - 3 days (New C3) alectinib Sensitive : A1 Future Medicine - 3d	alectinib Sensitive: A1 - Approval Future Medicine - 3 days alectinib Sensitive : A1 Future Medicine - 3 days - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval ASCO 2023 - 3 days (New C3) trastuzumab + pertuzumab Sensitive : A1 ASCO 2023 - 3d	trastuzumab + pertuzumab Sensitive: A1 - Approval ASCO 2023 - 3 days trastuzumab + pertuzumab Sensitive : A1 ASCO 2023 - 3 days - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 3d	sacituzumab govitecan-hziy Sensitive: A1 - Approval ASCO 2023 - 3 days sacituzumab govitecan-hziy Sensitive : A1 ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) abemaciclib Sensitive : A1 ASCO 2023 - 3d	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 3 days abemaciclib Sensitive : A1 ASCO 2023 - 3 days - (New B)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab-gxly Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) dostarlimab-gxly Sensitive : A1 ASCO 2023 - 3d	dostarlimab-gxly Sensitive: A1 - Approval ASCO 2023 - 3 days dostarlimab-gxly Sensitive : A1 ASCO 2023 - 3 days - (New B)
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval ASCO 2023 - 3 days (New B) pembrolizumab Sensitive : A1 ASCO 2023 - 3d	pembrolizumab Sensitive: A1 - Approval ASCO 2023 - 3 days pembrolizumab Sensitive : A1 ASCO 2023 - 3 days - (New B)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) palbociclib Sensitive : B ASCO 2023 - 3d	palbociclib Sensitive: B - Late Trials ASCO 2023 - 3 days palbociclib Sensitive : B ASCO 2023 - 3 days - (New B)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: B - Late Trials ASCO 2023 - 3 days (New C3) venetoclax Resistant : B ASCO 2023 - 3d	venetoclax Resistant: B - Late Trials ASCO 2023 - 3 days venetoclax Resistant : B ASCO 2023 - 3 days - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) G1T38 Sensitive : B ASCO 2023 - 3d	G1T38 Sensitive: B - Late Trials ASCO 2023 - 3 days G1T38 Sensitive : B ASCO 2023 - 3 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 3 days (New C3) dalpiciclib Sensitive : B ASCO 2023 - 3d	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 3 days dalpiciclib Sensitive : B ASCO 2023 - 3 days - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	toripalimab Sensitive: B - Late Trials ASCO 2023 - 3 days (New B) toripalimab Sensitive : B ASCO 2023 - 3d	toripalimab Sensitive: B - Late Trials ASCO 2023 - 3 days toripalimab Sensitive : B ASCO 2023 - 3 days - (New B)
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label ASCO 2023 - 3 days (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : C1 ASCO 2023 - 3d	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label ASCO 2023 - 3 days fam-trastuzumab deruxtecan-nxki Sensitive : C1 ASCO 2023 - 3 days - (New C3)
ERBB3 expression	Breast Cancer	ERBB3 expression	Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 3 days (New C3) U3-1402 Sensitive : C2 ASCO 2023 - 3d	U3-1402 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 3 days U3-1402 Sensitive : C2 ASCO 2023 - 3 days - (New C3)
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	STRO-002 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 3 days (New C3) STRO-002 Sensitive : C2 ASCO 2023 - 3d	STRO-002 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 3 days STRO-002 Sensitive : C2 ASCO 2023 - 3 days - (New C3)
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) FORE-8394 Sensitive : C3 ASCO 2023 - 3d	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) PD1 inhibitor Sensitive : C3 ASCO 2023 - 3d	PD1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 3 days PD1 inhibitor Sensitive : C3 ASCO 2023 - 3 days - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	docetaxel Resistant: C3 – Early Trials Lung Cancer - 3 days (New C3) docetaxel Resistant : C3 Lung Cancer - 3d	docetaxel Resistant: C3 – Early Trials Lung Cancer - 3 days docetaxel Resistant : C3 Lung Cancer - 3 days - (New C3)
BRAF V600	Glioma	BRAF V600	Glioma	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) FORE-8394 Sensitive : C3 ASCO 2023 - 3d	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
BRAF V600	Thyroid Gland Anaplastic Carcinoma	BRAF V600	Thyroid Gland Anaplastic Carcinoma	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) FORE-8394 Sensitive : C3 ASCO 2023 - 3d	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) FORE-8394 Sensitive : C3 ASCO 2023 - 3d	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + BCA101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) pembrolizumab + BCA101 Sensitive : C3 ASCO 2023 - 3d	pembrolizumab + BCA101 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + BCA101 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
BRAF V600	Ovarian Cancer	BRAF V600	Ovarian Cancer	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) FORE-8394 Sensitive : C3 ASCO 2023 - 3d	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BL-B01D1 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) BL-B01D1 Sensitive : C3 ASCO 2023 - 3d	BL-B01D1 Sensitive: C3 – Early Trials ASCO 2023 - 3 days BL-B01D1 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
HER-2 expression	Lung Cancer	HER-2 expression	Lung Cancer	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) DF1001 Sensitive : C3 ASCO 2023 - 3d	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days DF1001 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) DF1001 Sensitive : C3 ASCO 2023 - 3d	DF1001 Sensitive: C3 – Early Trials ASCO 2023 - 3 days DF1001 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	UCPVax Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) UCPVax Sensitive : C3 ASCO 2023 - 3d	UCPVax Sensitive: C3 – Early Trials ASCO 2023 - 3 days UCPVax Sensitive : C3 ASCO 2023 - 3 days - (New C3)
IDH2 mutation	Glioma	IDH2 mutation	Glioma	PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) PRT811 Sensitive : C3 ASCO 2023 - 3d	PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days PRT811 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
IDH1 mutation	Glioma	IDH1 mutation	Glioma	PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) PRT811 Sensitive : C3 ASCO 2023 - 3d	PRT811 Sensitive: C3 – Early Trials ASCO 2023 - 3 days PRT811 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
RSPO3 fusion	Gastrointestinal Stromal Tumor	RSPO3 fusion	Gastrointestinal Stromal Tumor	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) pembrolizumab + CGX1321 Sensitive : C3 ASCO 2023 - 3d	pembrolizumab + CGX1321 Sensitive: C3 – Early Trials ASCO 2023 - 3 days pembrolizumab + CGX1321 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
AGK-BRAF fusion	Melanoma	AGK-BRAF fusion	Melanoma	FORE-8394 Resistant: C4 – Case Studies ASCO 2023 - 3 days (New C4) FORE-8394 Resistant : C4 ASCO 2023 - 3d	FORE-8394 Resistant: C4 – Case Studies ASCO 2023 - 3 days FORE-8394 Resistant : C4 ASCO 2023 - 3 days - (New C4)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days (New B) befotertinib Sensitive : B Lancet Respir Med - 4d	befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days befotertinib Sensitive : B Lancet Respir Med - 4 days - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days (New B) befotertinib Sensitive : B Lancet Respir Med - 4d	befotertinib Sensitive: B - Late Trials Lancet Respir Med - 4 days befotertinib Sensitive : B Lancet Respir Med - 4 days - (New B)
EGFR negative	Lung Non-Squamous Non-Small Cell Cancer	EGFR negative	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: C3 – Early Trials Cancer Med - 4 days (New C3) bevacizumab Sensitive : C3 Cancer Med - 4d	bevacizumab Sensitive: C3 – Early Trials Cancer Med - 4 days bevacizumab Sensitive : C3 Cancer Med - 4 days - (New C3)
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days (New C4) pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 4d	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 4 days - (New C4)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days (New D) sotorasib + OTS514 Sensitive : D J Cell Mol Med - 4d	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days sotorasib + OTS514 Sensitive : D J Cell Mol Med - 4 days - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days (New D) OTS514 Sensitive : D J Cell Mol Med - 4d	OTS514 Sensitive: D – Preclinical J Cell Mol Med - 4 days OTS514 Sensitive : D J Cell Mol Med - 4 days - (New D)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: A2 - Guideline Sci Rep - 5 days (New C3) EGFR inhibitor Sensitive : A2 Sci Rep - 5d	EGFR inhibitor Sensitive: A2 - Guideline Sci Rep - 5 days EGFR inhibitor Sensitive : A2 Sci Rep - 5 days - (New C3)
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	osimertinib Resistant: C1 - Off-label Gan To Kagaku Ryoho - 5 days (New C4) osimertinib Resistant : C1 Gan To Kagaku Ryoho - 5d	osimertinib Resistant: C1 - Off-label Gan To Kagaku Ryoho - 5 days osimertinib Resistant : C1 Gan To Kagaku Ryoho - 5 days - (New C4)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	DAY101 Sensitive: C3 – Early Trials Cancer Chemother Pharmacol - 5 days (New C3) DAY101 Sensitive : C3 Cancer Chemother Pharmacol - 5d	DAY101 Sensitive: C3 – Early Trials Cancer Chemother Pharmacol - 5 days DAY101 Sensitive : C3 Cancer Chemother Pharmacol - 5 days - (New C3)
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	pralsetinib Sensitive: A2 - Guideline Cancer Res Treat - 6 days (New C3) pralsetinib Sensitive : A2 Cancer Res Treat - 6d	pralsetinib Sensitive: A2 - Guideline Cancer Res Treat - 6 days pralsetinib Sensitive : A2 Cancer Res Treat - 6 days - (New C3)
LDH elevation	Renal Cell Carcinoma	LDH elevation	Renal Cell Carcinoma	axitinib Resistant: C3 – Early Trials Kidney Cancer - 6 days (New C3) axitinib Resistant : C3 Kidney Cancer - 6d	axitinib Resistant: C3 – Early Trials Kidney Cancer - 6 days axitinib Resistant : C3 Kidney Cancer - 6 days - (New C3)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval PharmiWeb - 1 week (New A2) darolutamide Sensitive : A1 PharmiWeb - 1wk	darolutamide Sensitive: A1 - Approval PharmiWeb - 1 week darolutamide Sensitive : A1 PharmiWeb - 1 week - (New A2)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	epcoritamab Sensitive: A1 - Approval FDA - 1 week (New A1) epcoritamab Sensitive : A1 FDA - 1wk	epcoritamab Sensitive: A1 - Approval FDA - 1 week epcoritamab Sensitive : A1 FDA - 1 week - (New A1)
ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Resistant: A2 - Guideline ASCO.org - 1 week (New A2) alpelisib Resistant : A2 ASCO.org - 1wk	alpelisib Resistant: A2 - Guideline ASCO.org - 1 week alpelisib Resistant : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	elacestrant Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) elacestrant Sensitive : A2 ASCO.org - 1wk	elacestrant Sensitive: A2 - Guideline ASCO.org - 1 week elacestrant Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) everolimus Sensitive : A2 ASCO.org - 1wk	everolimus Sensitive: A2 - Guideline ASCO.org - 1 week everolimus Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) tamoxifen Sensitive : A2 ASCO.org - 1wk	tamoxifen Sensitive: A2 - Guideline ASCO.org - 1 week tamoxifen Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) Aromatase inhibitor Sensitive : A2 ASCO.org - 1wk	Aromatase inhibitor Sensitive: A2 - Guideline ASCO.org - 1 week Aromatase inhibitor Sensitive : A2 ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline ASCO.org - 1 week (New A2) fulvestrant Sensitive : A2 ASCO.org - 1wk	fulvestrant Sensitive: A2 - Guideline ASCO.org - 1 week fulvestrant Sensitive : A2 ASCO.org - 1 week - (New A2)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + eftilagimod alpha Sensitive: B - Late Trials Immutep Limited Press Release - 1 week (New C3) pembrolizumab + eftilagimod alpha Sensitive : B Immutep Limited Press Release - 1wk	pembrolizumab + eftilagimod alpha Sensitive: B - Late Trials Immutep Limited Press Release - 1 week pembrolizumab + eftilagimod alpha Sensitive : B Immutep Limited Press Release - 1 week - (New C3)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 1 week (New C3) TPX-0005 Sensitive : B Zai Lab Press Release - 1wk	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 1 week TPX-0005 Sensitive : B Zai Lab Press Release - 1 week - (New C3)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week (New B) IMPT-314 Sensitive : B PRNewswire - 1wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week IMPT-314 Sensitive : B PRNewswire - 1 week - (New B)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week (New B) IMPT-314 Sensitive : B PRNewswire - 1wk	IMPT-314 Sensitive: B - Late Trials PRNewswire - 1 week IMPT-314 Sensitive : B PRNewswire - 1 week - (New B)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 1 week (New C3) osimertinib Sensitive : A1 J Cancer Res Clin Oncol - 1wk	osimertinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 1 week osimertinib Sensitive : A1 J Cancer Res Clin Oncol - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval J Clin Oncol - 1 week (New C3) ribociclib Sensitive : A1 J Clin Oncol - 1wk	ribociclib Sensitive: A1 - Approval J Clin Oncol - 1 week ribociclib Sensitive : A1 J Clin Oncol - 1 week - (New C3)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval Ann Oncol - 1 week (New C3) bevacizumab + olaparib Sensitive : A1 Ann Oncol - 1wk	bevacizumab + olaparib Sensitive: A1 - Approval Ann Oncol - 1 week bevacizumab + olaparib Sensitive : A1 Ann Oncol - 1 week - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	panitumumab Sensitive: A1 - Approval JAMA Oncol - 1 week (New C3) panitumumab Sensitive : A1 JAMA Oncol - 1wk	panitumumab Sensitive: A1 - Approval JAMA Oncol - 1 week panitumumab Sensitive : A1 JAMA Oncol - 1 week - (New C3)
MSI-H/dMMR	Thyroid Gland Papillary Carcinoma	MSI-H/dMMR	Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week (New A2) pembrolizumab Sensitive : A2 NCCN - 1wk	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week pembrolizumab Sensitive : A2 NCCN - 1 week - (New A2)
PD-L1 overexpression	Bladder Cancer	PD-L1 overexpression	Bladder Cancer	atezolizumab Sensitive: C1 - Off-label Int J Radiat Oncol Biol Phys - 1 week (New C3) atezolizumab Sensitive : C1 Int J Radiat Oncol Biol Phys - 1wk	atezolizumab Sensitive: C1 - Off-label Int J Radiat Oncol Biol Phys - 1 week atezolizumab Sensitive : C1 Int J Radiat Oncol Biol Phys - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria Ann Oncol - 1 week (New C3) U3-1402 Sensitive : C2 Ann Oncol - 1wk	U3-1402 Sensitive: C2 – Inclusion Criteria Ann Oncol - 1 week U3-1402 Sensitive : C2 Ann Oncol - 1 week - (New C3)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	gefitinib + tepotinib Sensitive: C3 – Early Trials Clin Cancer Res - 1 week (New C3) gefitinib + tepotinib Sensitive : C3 Clin Cancer Res - 1wk	gefitinib + tepotinib Sensitive: C3 – Early Trials Clin Cancer Res - 1 week gefitinib + tepotinib Sensitive : C3 Clin Cancer Res - 1 week - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib + afatinib Sensitive: C3 – Early Trials Cancer Res Treat - 1 week (New C3) osimertinib + afatinib Sensitive : C3 Cancer Res Treat - 1wk	osimertinib + afatinib Sensitive: C3 – Early Trials Cancer Res Treat - 1 week osimertinib + afatinib Sensitive : C3 Cancer Res Treat - 1 week - (New C3)
KDM1A expression	Small Cell Lung Cancer	KDM1A expression	Small Cell Lung Cancer	nivolumab + ipilimumab Resistant: C3 – Early Trials J Thorac Oncol - 1 week (New C3) nivolumab + ipilimumab Resistant : C3 J Thorac Oncol - 1wk	nivolumab + ipilimumab Resistant: C3 – Early Trials J Thorac Oncol - 1 week nivolumab + ipilimumab Resistant : C3 J Thorac Oncol - 1 week - (New C3)
KDM1A expression	Small Cell Lung Cancer	KDM1A expression	Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials J Thorac Oncol - 1 week (New C3) nivolumab Resistant : C3 J Thorac Oncol - 1wk	nivolumab Resistant: C3 – Early Trials J Thorac Oncol - 1 week nivolumab Resistant : C3 J Thorac Oncol - 1 week - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 1 week (New C3) Immunotherapy + Angiogenesis inhibitor Sensitive : C3 BMC Pulm Med - 1wk	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 1 week Immunotherapy + Angiogenesis inhibitor Sensitive : C3 BMC Pulm Med - 1 week - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials BMC Pulm Med - 1 week (New C3) PD1 inhibitor + Angiogenesis inhibitor Resistant : C3 BMC Pulm Med - 1wk	PD1 inhibitor + Angiogenesis inhibitor Resistant: C3 – Early Trials BMC Pulm Med - 1 week PD1 inhibitor + Angiogenesis inhibitor Resistant : C3 BMC Pulm Med - 1 week - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	enzalutamide capsule + fulvestrant Sensitive: C3 – Early Trials NPJ Breast Cancer - 1 week (New C3) enzalutamide capsule + fulvestrant Sensitive : C3 NPJ Breast Cancer - 1wk	enzalutamide capsule + fulvestrant Sensitive: C3 – Early Trials NPJ Breast Cancer - 1 week enzalutamide capsule + fulvestrant Sensitive : C3 NPJ Breast Cancer - 1 week - (New C3)
EGFR mutation + SYK overexpression	Non Small Cell Lung Cancer	EGFR mutation + SYK overexpression	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Signal Transduct Target Ther - 1 week (New C3) EGFR inhibitor Sensitive : C3 Signal Transduct Target Ther - 1wk	EGFR inhibitor Sensitive: C3 – Early Trials Signal Transduct Target Ther - 1 week EGFR inhibitor Sensitive : C3 Signal Transduct Target Ther - 1 week - (New C3)
PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 1 week (New C3) Immunotherapy + Angiogenesis inhibitor Sensitive : C3 BMC Pulm Med - 1wk	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 1 week Immunotherapy + Angiogenesis inhibitor Sensitive : C3 BMC Pulm Med - 1 week - (New C3)
PD-L1 expression	Lung Adenocarcinoma	PD-L1 expression	Lung Adenocarcinoma	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 1 week (New C3) Immunotherapy + Angiogenesis inhibitor Sensitive : C3 BMC Pulm Med - 1wk	Immunotherapy + Angiogenesis inhibitor Sensitive: C3 – Early Trials BMC Pulm Med - 1 week Immunotherapy + Angiogenesis inhibitor Sensitive : C3 BMC Pulm Med - 1 week - (New C3)
KIF5B-RET fusion	Lung Adenocarcinoma	KIF5B-RET fusion	Lung Adenocarcinoma	selpercatinib Sensitive: C4 – Case Studies Front Oncol - 1 week (New C4) selpercatinib Sensitive : C4 Front Oncol - 1wk	selpercatinib Sensitive: C4 – Case Studies Front Oncol - 1 week selpercatinib Sensitive : C4 Front Oncol - 1 week - (New C4)
MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	SCC244 Sensitive: D – Preclinical Signal Transduct Target Ther - 1 week (New D) SCC244 Sensitive : D Signal Transduct Target Ther - 1wk	SCC244 Sensitive: D – Preclinical Signal Transduct Target Ther - 1 week SCC244 Sensitive : D Signal Transduct Target Ther - 1 week - (New D)
MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	MET overexpression + SYK overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: D – Preclinical Signal Transduct Target Ther - 1 week (New D) capmatinib Sensitive : D Signal Transduct Target Ther - 1wk	capmatinib Sensitive: D – Preclinical Signal Transduct Target Ther - 1 week capmatinib Sensitive : D Signal Transduct Target Ther - 1 week - (New D)
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval N Engl J Med - 2 weeks (New B) venetoclax + obinutuzumab Sensitive : A1 N Engl J Med - 2wk	venetoclax + obinutuzumab Sensitive: A1 - Approval N Engl J Med - 2 weeks venetoclax + obinutuzumab Sensitive : A1 N Engl J Med - 2 weeks - (New B)
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval Blood Cancer J - 2 weeks (New B) isatuximab-irfc Sensitive : A1 Blood Cancer J - 2wk	isatuximab-irfc Sensitive: A1 - Approval Blood Cancer J - 2 weeks isatuximab-irfc Sensitive : A1 Blood Cancer J - 2 weeks - (New B)
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) venetoclax Sensitive : A2 EHA 2023 - 2wk	venetoclax Sensitive: A2 - Guideline EHA 2023 - 2 weeks venetoclax Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) venetoclax Sensitive : A2 EHA 2023 - 2wk	venetoclax Sensitive: A2 - Guideline EHA 2023 - 2 weeks venetoclax Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) midostaurin Sensitive : A2 EHA 2023 - 2wk	midostaurin Sensitive: A2 - Guideline EHA 2023 - 2 weeks midostaurin Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + zanubrutinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab + zanubrutinib Sensitive : A2 NCCN - 2wk	rituximab + zanubrutinib Sensitive: A2 - Guideline NCCN - 2 weeks rituximab + zanubrutinib Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + acalabrutinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab + acalabrutinib Sensitive : A2 NCCN - 2wk	rituximab + acalabrutinib Sensitive: A2 - Guideline NCCN - 2 weeks rituximab + acalabrutinib Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-Maxi-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-Maxi-CHOP Sensitive : A2 NCCN - 2wk	R-Maxi-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-Maxi-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAP + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAP + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAP + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAP + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAX + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAX + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAX + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAX + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	R-DHAC + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) R-DHAC + R-CHOP Sensitive : A2 NCCN - 2wk	R-DHAC + R-CHOP Sensitive: A2 - Guideline NCCN - 2 weeks R-DHAC + R-CHOP Sensitive : A2 NCCN - 2 weeks - (New A2)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	tucatinib Sensitive: B - Late Trials J Natl Cancer Inst - 2 weeks (New D) tucatinib Sensitive : B J Natl Cancer Inst - 2wk	tucatinib Sensitive: B - Late Trials J Natl Cancer Inst - 2 weeks tucatinib Sensitive : B J Natl Cancer Inst - 2 weeks - (New D)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: B - Late Trials EHA 2023 - 2 weeks (New C3) FLT3 inhibitor Sensitive : B EHA 2023 - 2wk	FLT3 inhibitor Sensitive: B - Late Trials EHA 2023 - 2 weeks FLT3 inhibitor Sensitive : B EHA 2023 - 2 weeks - (New C3)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 2 weeks (New B) nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 2wk	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials N Engl J Med - 2 weeks nivolumab + ipilimumab + cabozantinib tablet Sensitive : B N Engl J Med - 2 weeks - (New B)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks (New B) ACR-368 Sensitive : B GlobeNewswire - 2wk	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks ACR-368 Sensitive : B GlobeNewswire - 2 weeks - (New B)
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks (New B) ACR-368 Sensitive : B GlobeNewswire - 2wk	ACR-368 Sensitive: B - Late Trials GlobeNewswire - 2 weeks ACR-368 Sensitive : B GlobeNewswire - 2 weeks - (New B)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) gilteritinib Sensitive : A1 EHA 2023 - 2wk	gilteritinib Sensitive: A1 - Approval EHA 2023 - 2 weeks gilteritinib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	dasatinib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) dasatinib Sensitive : A1 EHA 2023 - 2wk	dasatinib Sensitive: A1 - Approval EHA 2023 - 2 weeks dasatinib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	asciminib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) asciminib Sensitive : A1 EHA 2023 - 2wk	asciminib Sensitive: A1 - Approval EHA 2023 - 2 weeks asciminib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) midostaurin Sensitive : A1 EHA 2023 - 2wk	midostaurin Sensitive: A1 - Approval EHA 2023 - 2 weeks midostaurin Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	olutasidenib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) olutasidenib Sensitive : A1 EHA 2023 - 2wk	olutasidenib Sensitive: A1 - Approval EHA 2023 - 2 weeks olutasidenib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) ponatinib Sensitive : A1 EHA 2023 - 2wk	ponatinib Sensitive: A1 - Approval EHA 2023 - 2 weeks ponatinib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) nilotinib Sensitive : A1 EHA 2023 - 2wk	nilotinib Sensitive: A1 - Approval EHA 2023 - 2 weeks nilotinib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval NICE - 2 weeks (New A2) olaparib Sensitive : A1 NICE - 2wk	olaparib Sensitive: A1 - Approval NICE - 2 weeks olaparib Sensitive : A1 NICE - 2 weeks - (New A2)
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval NICE - 2 weeks (New A2) olaparib Sensitive : A1 NICE - 2wk	olaparib Sensitive: A1 - Approval NICE - 2 weeks olaparib Sensitive : A1 NICE - 2 weeks - (New A2)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	imatinib Sensitive: A1 - Approval EHA 2023 - 2 weeks (New C3) imatinib Sensitive : A1 EHA 2023 - 2wk	imatinib Sensitive: A1 - Approval EHA 2023 - 2 weeks imatinib Sensitive : A1 EHA 2023 - 2 weeks - (New C3)
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval Precision Oncology News - 2 weeks (New A2) trametinib + dabrafenib Sensitive : A1 Precision Oncology News - 2wk	trametinib + dabrafenib Sensitive: A1 - Approval Precision Oncology News - 2 weeks trametinib + dabrafenib Sensitive : A1 Precision Oncology News - 2 weeks - (New A2)
IDH1 R132	Acute Myelogenous Leukemia	IDH1 R132	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval Servier Press Release - 2 weeks (New A1) ivosidenib Sensitive : A1 Servier Press Release - 2wk	ivosidenib Sensitive: A1 - Approval Servier Press Release - 2 weeks ivosidenib Sensitive : A1 Servier Press Release - 2 weeks - (New A1)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Innovent Biologics Press Release - 2 weeks (New A1) sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1 Innovent Biologics Press Release - 2wk	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Innovent Biologics Press Release - 2 weeks sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1 Innovent Biologics Press Release - 2 weeks - (New A1)
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval Servier Press Release - 2 weeks (New A1) ivosidenib Sensitive : A1 Servier Press Release - 2wk	ivosidenib Sensitive: A1 - Approval Servier Press Release - 2 weeks ivosidenib Sensitive : A1 Servier Press Release - 2 weeks - (New A1)
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	nilotinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) nilotinib Sensitive : A2 EHA 2023 - 2wk	nilotinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks nilotinib Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) gilteritinib Sensitive : A2 EHA 2023 - 2wk	gilteritinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks gilteritinib Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline JAMA Oncol - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : A2 JAMA Oncol - 2wk	trastuzumab + pertuzumab Sensitive: A2 - Guideline JAMA Oncol - 2 weeks trastuzumab + pertuzumab Sensitive : A2 JAMA Oncol - 2 weeks - (New C3)
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) gemtuzumab ozogamicin Sensitive : A2 EHA 2023 - 2wk	gemtuzumab ozogamicin Sensitive: A2 - Guideline EHA 2023 - 2 weeks gemtuzumab ozogamicin Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New C3) sorafenib Sensitive : A2 EHA 2023 - 2wk	sorafenib Sensitive: A2 - Guideline EHA 2023 - 2 weeks sorafenib Sensitive : A2 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks (New B) ponatinib Sensitive : A2 EHA 2023 - 2wk	ponatinib Sensitive: A2 - Guideline EHA 2023 - 2 weeks ponatinib Sensitive : A2 EHA 2023 - 2 weeks - (New B)
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials EHA 2023 - 2 weeks (New C3) venetoclax Sensitive : B EHA 2023 - 2wk	venetoclax Sensitive: B - Late Trials EHA 2023 - 2 weeks venetoclax Sensitive : B EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: B - Late Trials EHA 2023 - 2 weeks (New B) quizartinib Sensitive : B EHA 2023 - 2wk	quizartinib Sensitive: B - Late Trials EHA 2023 - 2 weeks quizartinib Sensitive : B EHA 2023 - 2 weeks - (New B)
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials EHA 2023 - 2 weeks (New C3) azacitidine Resistant : B EHA 2023 - 2wk	azacitidine Resistant: B - Late Trials EHA 2023 - 2 weeks azacitidine Resistant : B EHA 2023 - 2 weeks - (New C3)
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials EHA 2023 - 2 weeks (New B) zanubrutinib Sensitive : B EHA 2023 - 2wk	zanubrutinib Sensitive: B - Late Trials EHA 2023 - 2 weeks zanubrutinib Sensitive : B EHA 2023 - 2 weeks - (New B)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	ponatinib Sensitive: C1 - Off-label EHA 2023 - 2 weeks (New C3) ponatinib Sensitive : C1 EHA 2023 - 2wk	ponatinib Sensitive: C1 - Off-label EHA 2023 - 2 weeks ponatinib Sensitive : C1 EHA 2023 - 2 weeks - (New C3)
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	ivosidenib Sensitive: C1 - Off-label EHA 2023 - 2 weeks (New C3) ivosidenib Sensitive : C1 EHA 2023 - 2wk	ivosidenib Sensitive: C1 - Off-label EHA 2023 - 2 weeks ivosidenib Sensitive : C1 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	Acute Myelogenous Leukemia	BCR-ABL1 fusion	Acute Myelogenous Leukemia	asciminib Sensitive: C1 - Off-label EHA 2023 - 2 weeks (New C3) asciminib Sensitive : C1 EHA 2023 - 2wk	asciminib Sensitive: C1 - Off-label EHA 2023 - 2 weeks asciminib Sensitive : C1 EHA 2023 - 2 weeks - (New C3)
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	D-1553 Sensitive: C2 – Inclusion Criteria Cancer Sci - 2 weeks (New D) D-1553 Sensitive : C2 Cancer Sci - 2wk	D-1553 Sensitive: C2 – Inclusion Criteria Cancer Sci - 2 weeks D-1553 Sensitive : C2 Cancer Sci - 2 weeks - (New D)
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks (New C3) KO-539 Sensitive : C2 EHA 2023 - 2wk	KO-539 Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks KO-539 Sensitive : C2 EHA 2023 - 2 weeks - (New C3)
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks (New C3) blinatumomab + inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2wk	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks blinatumomab + inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2 weeks - (New C3)
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks (New C3) inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2wk	inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria EHA 2023 - 2 weeks inotuzumab ozogamicin Sensitive : C2 EHA 2023 - 2 weeks - (New C3)
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax + gilteritinib Sensitive : C3 EHA 2023 - 2wk	venetoclax + gilteritinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax + gilteritinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax + gilteritinib Sensitive : C3 EHA 2023 - 2wk	venetoclax + gilteritinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax + gilteritinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib + blinatumomab Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) ponatinib + blinatumomab Sensitive : C3 EHA 2023 - 2wk	ponatinib + blinatumomab Sensitive: C3 – Early Trials EHA 2023 - 2 weeks ponatinib + blinatumomab Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax Sensitive : C3 EHA 2023 - 2wk	venetoclax Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) TP-0903 Sensitive : C3 EHA 2023 - 2wk	TP-0903 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks TP-0903 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks (New C3) pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2wk	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2 weeks - (New C3)
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks (New C3) pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2wk	pembrolizumab + MVP-S Sensitive: C3 – Early Trials Eur J Haematol - 2 weeks pembrolizumab + MVP-S Sensitive : C3 Eur J Haematol - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + camrelizumab Sensitive: C3 – Early Trials Int J Cancer - 2 weeks (New C3) cetuximab + camrelizumab Sensitive : C3 Int J Cancer - 2wk	cetuximab + camrelizumab Sensitive: C3 – Early Trials Int J Cancer - 2 weeks cetuximab + camrelizumab Sensitive : C3 Int J Cancer - 2 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib + ramucirumab Sensitive: C3 – Early Trials BMC Cancer - 2 weeks (New C3) afatinib + ramucirumab Sensitive : C3 BMC Cancer - 2wk	afatinib + ramucirumab Sensitive: C3 – Early Trials BMC Cancer - 2 weeks afatinib + ramucirumab Sensitive : C3 BMC Cancer - 2 weeks - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	A-1331852 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) A-1331852 Sensitive : C3 EHA 2023 - 2wk	A-1331852 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks A-1331852 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	ABT 263 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) ABT 263 Sensitive : C3 EHA 2023 - 2wk	ABT 263 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks ABT 263 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) olverembatinib Sensitive : C3 EHA 2023 - 2wk	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks olverembatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
IKZF1 deletion	B Acute Lymphoblastic Leukemia	IKZF1 deletion	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) CD19-targeted CAR-T immunotherapy Resistant : C3 EHA 2023 - 2wk	CD19-targeted CAR-T immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks CD19-targeted CAR-T immunotherapy Resistant : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	ponatinib + blinatumomab Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) ponatinib + blinatumomab Sensitive : C3 EHA 2023 - 2wk	ponatinib + blinatumomab Sensitive: C3 – Early Trials EHA 2023 - 2 weeks ponatinib + blinatumomab Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) flumatinib Sensitive : C3 EHA 2023 - 2wk	flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks flumatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) olverembatinib Sensitive : C3 EHA 2023 - 2wk	olverembatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks olverembatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) azacitidine Resistant : C3 EHA 2023 - 2wk	azacitidine Resistant: C3 – Early Trials EHA 2023 - 2 weeks azacitidine Resistant : C3 EHA 2023 - 2 weeks - (New C3)
WT1 overexpression	Acute Myelogenous Leukemia	WT1 overexpression	Acute Myelogenous Leukemia	azacitidine Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) azacitidine Resistant : C3 EHA 2023 - 2wk	azacitidine Resistant: C3 – Early Trials EHA 2023 - 2 weeks azacitidine Resistant : C3 EHA 2023 - 2 weeks - (New C3)
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	CyBorD Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) CyBorD Resistant : C3 EHA 2023 - 2wk	CyBorD Resistant: C3 – Early Trials EHA 2023 - 2 weeks CyBorD Resistant : C3 EHA 2023 - 2 weeks - (New C3)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) cytarabine Resistant : C3 EHA 2023 - 2wk	cytarabine Resistant: C3 – Early Trials EHA 2023 - 2 weeks cytarabine Resistant : C3 EHA 2023 - 2 weeks - (New C3)
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2wk	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2wk	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) midostaurin + gemtuzumab ozogamicin Sensitive : C3 EHA 2023 - 2wk	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials EHA 2023 - 2 weeks midostaurin + gemtuzumab ozogamicin Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) midostaurin + gemtuzumab ozogamicin Sensitive : C3 EHA 2023 - 2wk	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials EHA 2023 - 2 weeks midostaurin + gemtuzumab ozogamicin Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3 EHA 2023 - 2wk	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials EHA 2023 - 2 weeks cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax + sunitinib + I-BET151 Sensitive : C3 EHA 2023 - 2wk	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax + sunitinib + I-BET151 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
LMO2 overexpression	T Cell Non-Hodgkin Lymphoma	LMO2 overexpression	T Cell Non-Hodgkin Lymphoma	fluzoparib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) fluzoparib Sensitive : C3 EHA 2023 - 2wk	fluzoparib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks fluzoparib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
LDH elevation	Non-Hodgkin’s Lymphoma	LDH elevation	Non-Hodgkin’s Lymphoma	ARI-0001 Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) ARI-0001 Resistant : C3 EHA 2023 - 2wk	ARI-0001 Resistant: C3 – Early Trials EHA 2023 - 2 weeks ARI-0001 Resistant : C3 EHA 2023 - 2 weeks - (New C3)
Chr del(17p)	Diffuse Large B Cell Lymphoma	Chr del(17p)	Diffuse Large B Cell Lymphoma	Immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 EHA 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials EHA 2023 - 2 weeks Immunotherapy Resistant : C3 EHA 2023 - 2 weeks - (New C3)
TP53 deletion	Diffuse Large B Cell Lymphoma	TP53 deletion	Diffuse Large B Cell Lymphoma	Immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 EHA 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks Immunotherapy Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	brigatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) brigatinib Sensitive : C3 EHA 2023 - 2wk	brigatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks brigatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
IL6-L	Multiple Myeloma	IL6-L	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 EHA 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks PF-06863135 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
TNFRSF17 amplification	Multiple Myeloma	TNFRSF17 amplification	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 EHA 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks PF-06863135 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
CCL3-L	Multiple Myeloma	CCL3-L	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 EHA 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks PF-06863135 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
IL17C-L	Multiple Myeloma	IL17C-L	Multiple Myeloma	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) PF-06863135 Sensitive : C3 EHA 2023 - 2wk	PF-06863135 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks PF-06863135 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
CD19 expression + Chr t(8;21)	Acute Myelogenous Leukemia	CD19 expression + Chr t(8;21)	Acute Myelogenous Leukemia	CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) CD19-targeted CAR-T immunotherapy Sensitive : C3 EHA 2023 - 2wk	CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks CD19-targeted CAR-T immunotherapy Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3 EHA 2023 - 2wk	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials EHA 2023 - 2 weeks CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) midostaurin Sensitive : C3 EHA 2023 - 2wk	midostaurin Sensitive: C3 – Early Trials EHA 2023 - 2 weeks midostaurin Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	venetoclax + flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax + flumatinib Sensitive : C3 EHA 2023 - 2wk	venetoclax + flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax + flumatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	venetoclax + flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) venetoclax + flumatinib Sensitive : C3 EHA 2023 - 2wk	venetoclax + flumatinib Sensitive: C3 – Early Trials EHA 2023 - 2 weeks venetoclax + flumatinib Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	VRD Sensitive: C4 – Case Studies EHA 2023 - 2 weeks (New C4) VRD Sensitive : C4 EHA 2023 - 2wk	VRD Sensitive: C4 – Case Studies EHA 2023 - 2 weeks VRD Sensitive : C4 EHA 2023 - 2 weeks - (New C4)
Chr del(5q)	Multiple Myeloma	Chr del(5q)	Multiple Myeloma	VRD Sensitive: C4 – Case Studies EHA 2023 - 2 weeks (New C4) VRD Sensitive : C4 EHA 2023 - 2wk	VRD Sensitive: C4 – Case Studies EHA 2023 - 2 weeks VRD Sensitive : C4 EHA 2023 - 2 weeks - (New C4)
LILRB4 overexpression	Acute Myelogenous Leukemia	LILRB4 overexpression	Acute Myelogenous Leukemia	IO-202 Sensitive: C4 – Case Studies EHA 2023 - 2 weeks (New C4) IO-202 Sensitive : C4 EHA 2023 - 2wk	IO-202 Sensitive: C4 – Case Studies EHA 2023 - 2 weeks IO-202 Sensitive : C4 EHA 2023 - 2 weeks - (New C4)
FGFR2 amplification	Gastric Adenocarcinoma	FGFR2 amplification	Gastric Adenocarcinoma	nintedanib Sensitive: D – Preclinical Front Oncol - 2 weeks (New D) nintedanib Sensitive : D Front Oncol - 2wk	nintedanib Sensitive: D – Preclinical Front Oncol - 2 weeks nintedanib Sensitive : D Front Oncol - 2 weeks - (New D)
SLFN11 underexpression	Acute Myelogenous Leukemia	SLFN11 underexpression	Acute Myelogenous Leukemia	cytarabine Resistant: D – Preclinical EHA 2023 - 2 weeks (New D) cytarabine Resistant : D EHA 2023 - 2wk	cytarabine Resistant: D – Preclinical EHA 2023 - 2 weeks cytarabine Resistant : D EHA 2023 - 2 weeks - (New D)
CD70 expression	B Acute Lymphoblastic Leukemia	CD70 expression	B Acute Lymphoblastic Leukemia	CD70-targeted CAR-T immunotherapy Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) CD70-targeted CAR-T immunotherapy Sensitive : D EHA 2023 - 2wk	CD70-targeted CAR-T immunotherapy Sensitive: D – Preclinical EHA 2023 - 2 weeks CD70-targeted CAR-T immunotherapy Sensitive : D EHA 2023 - 2 weeks - (New D)
HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	INT-1B3 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) INT-1B3 Sensitive : D EHA 2023 - 2wk	INT-1B3 Sensitive: D – Preclinical EHA 2023 - 2 weeks INT-1B3 Sensitive : D EHA 2023 - 2 weeks - (New D)
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	crizotinib + LB-100 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) crizotinib + LB-100 Sensitive : D EHA 2023 - 2wk	crizotinib + LB-100 Sensitive: D – Preclinical EHA 2023 - 2 weeks crizotinib + LB-100 Sensitive : D EHA 2023 - 2 weeks - (New D)
KEAP1 expression	Chronic Lymphocytic Leukemia	KEAP1 expression	Chronic Lymphocytic Leukemia	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) ibrutinib + brusatol Sensitive : D EHA 2023 - 2wk	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks ibrutinib + brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
KEAP1 expression	Chronic Lymphocytic Leukemia	KEAP1 expression	Chronic Lymphocytic Leukemia	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) brusatol Sensitive : D EHA 2023 - 2wk	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
CD38 positive	Multiple Myeloma	CD38 positive	Multiple Myeloma	SAR442257 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) SAR442257 Sensitive : D EHA 2023 - 2wk	SAR442257 Sensitive: D – Preclinical EHA 2023 - 2 weeks SAR442257 Sensitive : D EHA 2023 - 2 weeks - (New D)
TSC2 C1450G	HER2 Positive Breast Cancer	TSC2 C1450G	HER2 Positive Breast Cancer	palbociclib + lapatinib Sensitive: D – Preclinical NPJ Breast Cancer - 2 weeks (New D) palbociclib + lapatinib Sensitive : D NPJ Breast Cancer - 2wk	palbociclib + lapatinib Sensitive: D – Preclinical NPJ Breast Cancer - 2 weeks palbociclib + lapatinib Sensitive : D NPJ Breast Cancer - 2 weeks - (New D)
TP73 overexpression	Multiple Myeloma	TP73 overexpression	Multiple Myeloma	epirubicin Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) epirubicin Sensitive : D EHA 2023 - 2wk	epirubicin Sensitive: D – Preclinical EHA 2023 - 2 weeks epirubicin Sensitive : D EHA 2023 - 2 weeks - (New D)
NFE2L2 expression	Chronic Lymphocytic Leukemia	NFE2L2 expression	Chronic Lymphocytic Leukemia	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) ibrutinib + brusatol Sensitive : D EHA 2023 - 2wk	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks ibrutinib + brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
NFE2L2 expression	Chronic Lymphocytic Leukemia	NFE2L2 expression	Chronic Lymphocytic Leukemia	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) brusatol Sensitive : D EHA 2023 - 2wk	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
KMT2A rearrangement + RAS mutation	B Acute Lymphoblastic Leukemia	KMT2A rearrangement + RAS mutation	B Acute Lymphoblastic Leukemia	selumetinib + SNDX-5613 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) selumetinib + SNDX-5613 Sensitive : D EHA 2023 - 2wk	selumetinib + SNDX-5613 Sensitive: D – Preclinical EHA 2023 - 2 weeks selumetinib + SNDX-5613 Sensitive : D EHA 2023 - 2 weeks - (New D)
KMT2A rearrangement + RAS mutation	Acute Myelogenous Leukemia	KMT2A rearrangement + RAS mutation	Acute Myelogenous Leukemia	selumetinib + SNDX-5613 Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) selumetinib + SNDX-5613 Sensitive : D EHA 2023 - 2wk	selumetinib + SNDX-5613 Sensitive: D – Preclinical EHA 2023 - 2 weeks selumetinib + SNDX-5613 Sensitive : D EHA 2023 - 2 weeks - (New D)
KRAS G12S	Lung Adenocarcinoma	KRAS G12S	Lung Adenocarcinoma	trametinib + RAIN-32 Sensitive: D – Preclinical J Thorac Oncol - 2 weeks (New D) trametinib + RAIN-32 Sensitive : D J Thorac Oncol - 2wk	trametinib + RAIN-32 Sensitive: D – Preclinical J Thorac Oncol - 2 weeks trametinib + RAIN-32 Sensitive : D J Thorac Oncol - 2 weeks - (New D)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks (New A1) lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3wk	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks lisocabtagene maraleucel Sensitive : A1 Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TCHP Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) TCHP Sensitive : A2 ESMO-BC 2023 - 3wk	TCHP Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks TCHP Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) trastuzumab + lapatinib Sensitive : A2 ESMO-BC 2023 - 3wk	trastuzumab + lapatinib Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks trastuzumab + lapatinib Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) Aromatase inhibitor Sensitive : A2 ESMO-BC 2023 - 3wk	Aromatase inhibitor Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks Aromatase inhibitor Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
TMB-H	Pancreatic Adenocarcinoma	TMB-H	Pancreatic Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) nivolumab + ipilimumab Sensitive : A2 NCCN - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 3 weeks nivolumab + ipilimumab Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	FOLFIRI Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) FOLFIRI Sensitive : A2 NCCN - 3wk	FOLFIRI Sensitive: A2 - Guideline NCCN - 3 weeks FOLFIRI Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	OFF Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) OFF Sensitive : A2 NCCN - 3wk	OFF Sensitive: A2 - Guideline NCCN - 3 weeks OFF Sensitive : A2 NCCN - 3 weeks - (New A2)
PD-L1 overexpression	Triple Negative Breast Cancer	PD-L1 overexpression	Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) pembrolizumab Sensitive : B ESMO-BC 2023 - 3wk	pembrolizumab Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks pembrolizumab Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials JAMA Netw Open - 3 weeks (New C3) Immunotherapy Sensitive : B JAMA Netw Open - 3wk	Immunotherapy Sensitive: B - Late Trials JAMA Netw Open - 3 weeks Immunotherapy Sensitive : B JAMA Netw Open - 3 weeks - (New C3)
EGFR mutation	Glioblastoma	EGFR mutation	Glioblastoma	ERAS-801 Sensitive: B - Late Trials GlobeNewswire - 3 weeks (New B) ERAS-801 Sensitive : B GlobeNewswire - 3wk	ERAS-801 Sensitive: B - Late Trials GlobeNewswire - 3 weeks ERAS-801 Sensitive : B GlobeNewswire - 3 weeks - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	AZD5363 Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) AZD5363 Sensitive : B ESMO-BC 2023 - 3wk	AZD5363 Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks AZD5363 Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
HER-2 underexpression + ER underexpression	Breast Cancer	HER-2 underexpression + ER underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New B) fam-trastuzumab deruxtecan-nxki Sensitive : B ESMO-BC 2023 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : B ESMO-BC 2023 - 3 weeks - (New B)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval J Thorac Oncol - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : A1 J Thorac Oncol - 3wk	nivolumab + ipilimumab Sensitive: A1 - Approval J Thorac Oncol - 3 weeks nivolumab + ipilimumab Sensitive : A1 J Thorac Oncol - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO-BC 2023 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) trastuzumab Sensitive : A1 ESMO-BC 2023 - 3wk	trastuzumab Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks trastuzumab Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) neratinib Sensitive : A1 ESMO-BC 2023 - 3wk	neratinib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks neratinib Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) palbociclib Sensitive : A1 ESMO-BC 2023 - 3wk	palbociclib Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks palbociclib Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks (New C3) pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 ESMO-BC 2023 - 3wk	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval ESMO-BC 2023 - 3 weeks pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1 ESMO-BC 2023 - 3 weeks - (New C3)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval Lancet Oncol - 3 weeks (New C3) trastuzumab + tucatinib Sensitive : A1 Lancet Oncol - 3wk	trastuzumab + tucatinib Sensitive: A1 - Approval Lancet Oncol - 3 weeks trastuzumab + tucatinib Sensitive : A1 Lancet Oncol - 3 weeks - (New C3)
FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval Immunogen Press Release - 3 weeks (New B) mirvetuximab soravtansine-gynx Sensitive : A1 Immunogen Press Release - 3wk	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval Immunogen Press Release - 3 weeks mirvetuximab soravtansine-gynx Sensitive : A1 Immunogen Press Release - 3 weeks - (New B)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	icotinib Sensitive: A2 - Guideline Invest New Drugs - 3 weeks (New C3) icotinib Sensitive : A2 Invest New Drugs - 3wk	icotinib Sensitive: A2 - Guideline Invest New Drugs - 3 weeks icotinib Sensitive : A2 Invest New Drugs - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks (New C3) capecitabine Sensitive : A2 ESMO-BC 2023 - 3wk	capecitabine Sensitive: A2 - Guideline ESMO-BC 2023 - 3 weeks capecitabine Sensitive : A2 ESMO-BC 2023 - 3 weeks - (New C3)
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	pembrolizumab Sensitive: A2 - Guideline Int J Surg Case Rep - 3 weeks (New C4) pembrolizumab Sensitive : A2 Int J Surg Case Rep - 3wk	pembrolizumab Sensitive: A2 - Guideline Int J Surg Case Rep - 3 weeks pembrolizumab Sensitive : A2 Int J Surg Case Rep - 3 weeks - (New C4)
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) sotorasib Sensitive : A2 NCCN - 3wk	sotorasib Sensitive: A2 - Guideline NCCN - 3 weeks sotorasib Sensitive : A2 NCCN - 3 weeks - (New A2)
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	adagrasib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) adagrasib Sensitive : A2 NCCN - 3wk	adagrasib Sensitive: A2 - Guideline NCCN - 3 weeks adagrasib Sensitive : A2 NCCN - 3 weeks - (New A2)
MSI-H/dMMR	Pancreatic Adenocarcinoma	MSI-H/dMMR	Pancreatic Adenocarcinoma	dostarlimab-gxly Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) dostarlimab-gxly Sensitive : A2 NCCN - 3wk	dostarlimab-gxly Sensitive: A2 - Guideline NCCN - 3 weeks dostarlimab-gxly Sensitive : A2 NCCN - 3 weeks - (New A2)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New C3) pertuzumab + ado-trastuzumab emtansine Sensitive : B ESMO-BC 2023 - 3wk	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks pertuzumab + ado-trastuzumab emtansine Sensitive : B ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks (New C3) trastuzumab-dkst Sensitive : B ESMO-BC 2023 - 3wk	trastuzumab-dkst Sensitive: B - Late Trials ESMO-BC 2023 - 3 weeks trastuzumab-dkst Sensitive : B ESMO-BC 2023 - 3 weeks - (New C3)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: B - Late Trials Lancet Respir Med - 3 weeks (New B) sintilimab Sensitive : B Lancet Respir Med - 3wk	sintilimab Sensitive: B - Late Trials Lancet Respir Med - 3 weeks sintilimab Sensitive : B Lancet Respir Med - 3 weeks - (New B)
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	olaparib Sensitive: C1 - Off-label ESMO-BC 2023 - 3 weeks (New C3) olaparib Sensitive : C1 ESMO-BC 2023 - 3wk	olaparib Sensitive: C1 - Off-label ESMO-BC 2023 - 3 weeks olaparib Sensitive : C1 ESMO-BC 2023 - 3 weeks - (New C3)
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	ceritinib Sensitive: C1 - Off-label Chin Med J (Engl) - 3 weeks (New C4) ceritinib Sensitive : C1 Chin Med J (Engl) - 3wk	ceritinib Sensitive: C1 - Off-label Chin Med J (Engl) - 3 weeks ceritinib Sensitive : C1 Chin Med J (Engl) - 3 weeks - (New C4)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) capecitabine + vinorelbine tartrate Sensitive : C2 ESMO-BC 2023 - 3wk	capecitabine + vinorelbine tartrate Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks capecitabine + vinorelbine tartrate Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ZW25 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) ZW25 Sensitive : C2 ESMO-BC 2023 - 3wk	ZW25 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks ZW25 Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + atezolizumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) trastuzumab + atezolizumab + pertuzumab Sensitive : C2 ESMO-BC 2023 - 3wk	trastuzumab + atezolizumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks trastuzumab + atezolizumab + pertuzumab Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	HLX22 Sensitive: C2 – Inclusion Criteria Invest New Drugs - 3 weeks (New C3) HLX22 Sensitive : C2 Invest New Drugs - 3wk	HLX22 Sensitive: C2 – Inclusion Criteria Invest New Drugs - 3 weeks HLX22 Sensitive : C2 Invest New Drugs - 3 weeks - (New C3)
HER-2 negative	Triple Negative Breast Cancer	HER-2 negative	Triple Negative Breast Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) U3-1402 Sensitive : C2 ESMO-BC 2023 - 3wk	U3-1402 Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks U3-1402 Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
HRD	Triple Negative Breast Cancer	HRD	Triple Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks (New C3) olaparib + durvalumab Sensitive : C2 ESMO-BC 2023 - 3wk	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO-BC 2023 - 3 weeks olaparib + durvalumab Sensitive : C2 ESMO-BC 2023 - 3 weeks - (New C3)
TMB-H	Colorectal Cancer	TMB-H	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks (New C3) Immunotherapy Sensitive : C3 JAMA Netw Open - 3wk	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks Immunotherapy Sensitive : C3 JAMA Netw Open - 3 weeks - (New C3)
TMB-H	Bladder Cancer	TMB-H	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks (New C3) Immunotherapy Sensitive : C3 JAMA Netw Open - 3wk	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks Immunotherapy Sensitive : C3 JAMA Netw Open - 3 weeks - (New C3)
TMB-H	Melanoma	TMB-H	Melanoma	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks (New C3) Immunotherapy Sensitive : C3 JAMA Netw Open - 3wk	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks Immunotherapy Sensitive : C3 JAMA Netw Open - 3 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) ARV-471 Sensitive : C3 ESMO-BC 2023 - 3wk	ARV-471 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks ARV-471 Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials BMC Pulm Med - 3 weeks (New C3) Immunotherapy Sensitive : C3 BMC Pulm Med - 3wk	Immunotherapy Sensitive: C3 – Early Trials BMC Pulm Med - 3 weeks Immunotherapy Sensitive : C3 BMC Pulm Med - 3 weeks - (New C3)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C3 – Early Trials Mol Cancer Ther - 3 weeks (New D) osimertinib + savolitinib Sensitive : C3 Mol Cancer Ther - 3wk	osimertinib + savolitinib Sensitive: C3 – Early Trials Mol Cancer Ther - 3 weeks osimertinib + savolitinib Sensitive : C3 Mol Cancer Ther - 3 weeks - (New D)
ARID1A mutation	Biliary Tract Cancer	ARID1A mutation	Biliary Tract Cancer	cisplatin + gemcitabine Resistant: C3 – Early Trials Cancer Res Treat - 3 weeks (New C3) cisplatin + gemcitabine Resistant : C3 Cancer Res Treat - 3wk	cisplatin + gemcitabine Resistant: C3 – Early Trials Cancer Res Treat - 3 weeks cisplatin + gemcitabine Resistant : C3 Cancer Res Treat - 3 weeks - (New C3)
HR positive	Leiomyosarcoma	HR positive	Leiomyosarcoma	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks (New C3) nivolumab + talimogene laherparepvec Sensitive : C3 ASGCT 2023 - 3wk	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks nivolumab + talimogene laherparepvec Sensitive : C3 ASGCT 2023 - 3 weeks - (New C3)
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	UCART123 Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks (New C3) UCART123 Sensitive : C3 ASGCT 2023 - 3wk	UCART123 Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks UCART123 Sensitive : C3 ASGCT 2023 - 3 weeks - (New C3)
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO-BC 2023 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks Immunotherapy Resistant : C3 ESMO-BC 2023 - 3 weeks - (New C3)
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO-BC 2023 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO-BC 2023 - 3 weeks Immunotherapy Resistant : C3 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESMO-BC 2023 - 3wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + HER-2 underexpression	Breast Cancer	HR positive + HER-2 underexpression	Breast Cancer	U3-1402 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) U3-1402 Sensitive : C3 ESMO-BC 2023 - 3wk	U3-1402 Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks U3-1402 Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks (New C3) abemaciclib Sensitive : C3 JCO Precis Oncol - 3wk	abemaciclib Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks abemaciclib Sensitive : C3 JCO Precis Oncol - 3 weeks - (New C3)
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	avelumab + axitinib Sensitive: C3 – Early Trials ESMO Open - 3 weeks (New C3) avelumab + axitinib Sensitive : C3 ESMO Open - 3wk	avelumab + axitinib Sensitive: C3 – Early Trials ESMO Open - 3 weeks avelumab + axitinib Sensitive : C3 ESMO Open - 3 weeks - (New C3)
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	avelumab + axitinib Sensitive: C3 – Early Trials ESMO Open - 3 weeks (New C3) avelumab + axitinib Sensitive : C3 ESMO Open - 3wk	avelumab + axitinib Sensitive: C3 – Early Trials ESMO Open - 3 weeks avelumab + axitinib Sensitive : C3 ESMO Open - 3 weeks - (New C3)
HR positive + ER overexpression	HER2 Negative Breast Cancer	HR positive + ER overexpression	HER2 Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) palbociclib Sensitive : C3 ESMO-BC 2023 - 3wk	palbociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks palbociclib Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + ER overexpression	HER2 Negative Breast Cancer	HR positive + ER overexpression	HER2 Negative Breast Cancer	ribociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks (New C3) ribociclib Sensitive : C3 ESMO-BC 2023 - 3wk	ribociclib Sensitive: C3 – Early Trials ESMO-BC 2023 - 3 weeks ribociclib Sensitive : C3 ESMO-BC 2023 - 3 weeks - (New C3)
EGFR L858R + EGFR T790M	Lung Cancer	EGFR L858R + EGFR T790M	Lung Cancer	osimertinib Sensitive: C4 – Case Studies Thorac Cancer - 3 weeks (New C4) osimertinib Sensitive : C4 Thorac Cancer - 3wk	osimertinib Sensitive: C4 – Case Studies Thorac Cancer - 3 weeks osimertinib Sensitive : C4 Thorac Cancer - 3 weeks - (New C4)
CCDC6-RET fusion	Triple Negative Breast Cancer	CCDC6-RET fusion	Triple Negative Breast Cancer	pralsetinib Sensitive: C4 – Case Studies Oncologist - 3 weeks (New C4) pralsetinib Sensitive : C4 Oncologist - 3wk	pralsetinib Sensitive: C4 – Case Studies Oncologist - 3 weeks pralsetinib Sensitive : C4 Oncologist - 3 weeks - (New C4)
ALK R1275Q	Neuroblastoma	ALK R1275Q	Neuroblastoma	lorlatinib Sensitive: C4 – Case Studies Nat Commun - 3 weeks (New C4) lorlatinib Sensitive : C4 Nat Commun - 3wk	lorlatinib Sensitive: C4 – Case Studies Nat Commun - 3 weeks lorlatinib Sensitive : C4 Nat Commun - 3 weeks - (New C4)
BRAF E501Q + PD-L1 negative	Lung Adenocarcinoma	BRAF E501Q + PD-L1 negative	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Respirol Case Rep - 3 weeks (New C4) pembrolizumab Sensitive : C4 Respirol Case Rep - 3wk	pembrolizumab Sensitive: C4 – Case Studies Respirol Case Rep - 3 weeks pembrolizumab Sensitive : C4 Respirol Case Rep - 3 weeks - (New C4)
ROR1 positive	Solid Tumor	ROR1 positive	Solid Tumor	LYL797 Sensitive: D – Preclinical ASGCT 2023 - 3 weeks (New D) LYL797 Sensitive : D ASGCT 2023 - 3wk	LYL797 Sensitive: D – Preclinical ASGCT 2023 - 3 weeks LYL797 Sensitive : D ASGCT 2023 - 3 weeks - (New D)
NUP98-KDM5A fusion	Acute Myelogenous Leukemia	NUP98-KDM5A fusion	Acute Myelogenous Leukemia	T-lymphocyte cell therapy Sensitive: D – Preclinical ASGCT 2023 - 3 weeks (New D) T-lymphocyte cell therapy Sensitive : D ASGCT 2023 - 3wk	T-lymphocyte cell therapy Sensitive: D – Preclinical ASGCT 2023 - 3 weeks T-lymphocyte cell therapy Sensitive : D ASGCT 2023 - 3 weeks - (New D)
TROP2 overexpression	Breast Cancer	TROP2 overexpression	Breast Cancer	DS-1062a Sensitive: D – Preclinical ESMO-BC 2023 - 3 weeks (New D) DS-1062a Sensitive : D ESMO-BC 2023 - 3wk	DS-1062a Sensitive: D – Preclinical ESMO-BC 2023 - 3 weeks DS-1062a Sensitive : D ESMO-BC 2023 - 3 weeks - (New D)
PIK3CA P449T	Colorectal Cancer	PIK3CA P449T	Colorectal Cancer	ribociclib Sensitive: D – Preclinical Anticancer Res - 3 weeks (New D) ribociclib Sensitive : D Anticancer Res - 3wk	ribociclib Sensitive: D – Preclinical Anticancer Res - 3 weeks ribociclib Sensitive : D Anticancer Res - 3 weeks - (New D)
RBM10 deletion + EGFR mutation	Lung Adenocarcinoma	RBM10 deletion + EGFR mutation	Lung Adenocarcinoma	osimertinib Sensitive: D – Preclinical Cancer Res - 3 weeks (New D) osimertinib Sensitive : D Cancer Res - 3wk	osimertinib Sensitive: D – Preclinical Cancer Res - 3 weeks osimertinib Sensitive : D Cancer Res - 3 weeks - (New D)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1